These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28653849)

  • 1. Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
    Choi JY; Fuerst R; Knapinska AM; Taylor AB; Smith L; Cao X; Hart PJ; Fields GB; Roush WR
    J Med Chem; 2017 Jul; 60(13):5816-5825. PubMed ID: 28653849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a putative Zn
    Fuerst R; Choi JY; Knapinska AM; Cameron MD; Ruiz C; Delmas A; Sundrud MS; Fields GB; Roush WR
    Bioorg Med Chem Lett; 2022 Nov; 76():129014. PubMed ID: 36202189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual High-Throughput Screening for Matrix Metalloproteinase Inhibitors.
    Choi JY; Fuerst R
    Methods Mol Biol; 2017; 1579():259-271. PubMed ID: 28299742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.
    Nara H; Kaieda A; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2017 Jan; 60(2):608-626. PubMed ID: 27966948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.
    Heim-Riether A; Taylor SJ; Liang S; Gao DA; Xiong Z; Michael August E; Collins BK; Farmer BT; Haverty K; Hill-Drzewi M; Junker HD; Mariana Margarit S; Moss N; Neumann T; Proudfoot JR; Keenan LS; Sekul R; Zhang Q; Li J; Farrow NA
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5321-4. PubMed ID: 19692239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
    Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
    J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies.
    Nuti E; Cuffaro D; Bernardini E; Camodeca C; Panelli L; Chaves S; Ciccone L; Tepshi L; Vera L; Orlandini E; Nencetti S; Stura EA; Santos MA; Dive V; Rossello A
    J Med Chem; 2018 May; 61(10):4421-4435. PubMed ID: 29727184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Recognition of the Catalytic Zinc(II) Ion in MMP-13: Structure-Based Evolution of an Allosteric Inhibitor to Dual Binding Mode Inhibitors with Improved Lipophilic Ligand Efficiencies.
    Fischer T; Riedl R
    Int J Mol Sci; 2016 Mar; 17(3):314. PubMed ID: 26938528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.
    Di Pizio A; Agamennone M; Tortorella P
    Curr Top Med Chem; 2016; 16(4):449-59. PubMed ID: 26268339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
    Dublanchet AC; Ducrot P; Andrianjara C; O'Gara M; Morales R; Compère D; Denis A; Blais S; Cluzeau P; Courté K; Hamon J; Moreau F; Prunet ML; Tertre A
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3787-90. PubMed ID: 16002291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain.
    Kothapalli R; Khan AM; Basappa ; Gopalsamy A; Chong YS; Annamalai L
    PLoS One; 2010 Aug; 5(8):e12494. PubMed ID: 20824169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potent and selective MMP-13 inhibitors.
    Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.
    Taylor SJ; Abeywardane A; Liang S; Muegge I; Padyana AK; Xiong Z; Hill-Drzewi M; Farmer B; Li X; Collins B; Li JX; Heim-Riether A; Proudfoot J; Zhang Q; Goldberg D; Zuvela-Jelaska L; Zaher H; Li J; Farrow NA
    J Med Chem; 2011 Dec; 54(23):8174-87. PubMed ID: 22017539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
    Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
    Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virtual Screening on MMP-13 Led to Discovering New Inhibitors Including a Non-Zinc Binding and a Micro Molar One: A Successful Example of Receptor Selection According to Cross-Docking Results for a Flexible Enzyme.
    Ramezani M; Shamsara J
    Comb Chem High Throughput Screen; 2017; 20(8):719-725. PubMed ID: 28814230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.